about
Chitosan-Poly (I:C)-PADRE Based Nanoparticles as Delivery Vehicles for Synthetic Peptide VaccinesThe performance of nanocarriers for transmucosal drug delivery.Nanoparticles as protein and gene carriers to mucosal surfaces.Nanoparticles for nasal vaccination.Vaccine delivery carriers: insights and future perspectives.Nanotherapies for the treatment of ocular diseases.Lymphatic Targeting of Nanosystems for Anticancer Drug Therapy.A comparative study of curcumin-loaded lipid-based nanocarriers in the treatment of inflammatory bowel disease.Biomaterials to suppress cancer stem cells and disrupt their tumoral niche.Emerging delivery platforms for mucosal administration of biopharmaceuticals: a critical update on nasal, pulmonary and oral routes.Implantable controlled release devices for BMP-7 delivery and suppression of glioblastoma initiating cells.Rational design of protamine nanocapsules as antigen delivery carriers.Polyaminoacid nanocapsules for drug delivery to the lymphatic system: Effect of the particle size.Ionically crosslinked chitosan/tripolyphosphate nanoparticles for oligonucleotide and plasmid DNA delivery.Surface coating of PLGA microparticles with protamine enhances their immunological performance through facilitated phagocytosis.Protamine-based nanoparticles as new antigen delivery systems.PLGA:poloxamer and PLGA:poloxamine blend nanoparticles: new carriers for gene delivery.Selective interaction of PEGylated polyglutamic acid nanocapsules with cancer cells in a 3D model of a metastatic lymph nodeAssessment of the permeability and toxicity of polymeric nanocapsules using the zebrafish model.The interaction of protamine nanocapsules with the intestinal epithelium: A mechanistic approach.Biodistribution of radiolabeled polyglutamic acid and PEG-polyglutamic acid nanocapsules.Colloidal stability of pluronic F68-coated PLGA nanoparticles: a variety of stabilisation mechanisms.Polymeric nanocapsules: a potential new therapy for corneal wound healing.Polymeric Nanocapsules for Vaccine Delivery: Influence of the Polymeric Shell on the Interaction With the Immune System.Ionically Crosslinked Chitosan Nanoparticles as Gene Delivery Systems: Effect of PEGylation Degree on In Vitro and In Vivo Gene TransferProtamine nanocapsules as carriers for oral peptide deliveryProtamine Nanocapsules for the Development of Thermostable Adjuvanted NanovaccinesDocetaxel-loaded polyglutamic acid-PEG nanocapsules for the treatment of metastatic cancerMulti-enveloping of particulated antigens with biopolymers and immunostimulant polynucleotides12. Biodegradable polymer nanoparticles as protein delivery systemsHighly cited research articles in Journal of Controlled Release: Commentaries and perspectives by authorsPreparation of Poly(Lactic Acid) (PLA) and Poly(Ethylene Oxide) (PEO) Nanoparticles as Carriers for Gene DeliveryConcomitant delivery of a CTL-restricted peptide antigen and CpG ODN by PLGA microparticles induces cellular immune responseA Protective Allergy Vaccine Based on CpG- and Protamine-Containing PLGA MicroparticlesDesign and characterisation of new nanoparticulate polymer blends for drug deliveryBilayer polymeric nanocapsules: A formulation approach for a thermostable and adjuvanted E. coli antigen vaccineA multifunctional drug nanocarrier for efficient anticancer therapySemisynthetic glycoconjugate based on dual role protein/PsaA as a pneumococcal vaccineVersatile protamine nanocapsules to restore miR-145 levels and interfere tumor growth in colorectal cancer cells
P50
Q36101913-11786913-B1D7-4196-A188-2DAAB826149FQ36527739-D11368BD-8E3F-4F41-AFB5-BE34ECE021A4Q37331802-AD8D8DB8-F40B-4743-8B39-6EA4B773029AQ37361736-53307AC5-3454-488F-BEB5-C27E15DFA069Q38007823-E0CC8EE9-23E7-49BE-AF5F-2A6E140B08C6Q38366039-4B2B83ED-E3A4-46D1-833D-E898BDED4A24Q38671253-7624698B-3BA7-4ACB-AA75-67CBF1147BE8Q38782668-6F955FD5-AE46-4847-B1CD-8F1826AB7F99Q38784531-2A380397-0C43-4FFB-8B0C-4644AC1FEF14Q38847705-7E6519F2-C8E8-4DFB-AD11-C65FB0182DA3Q39035973-9B43D99C-273D-4792-BC49-D8E236A3E07DQ39179982-EA8EDD2A-D0FF-4777-9F58-01FFC98B704FQ39745826-7D1B6B24-CC84-4FFC-B2A2-449534BE59A4Q39815989-EE77E36C-9B14-4957-8817-918B9F3EF1FCQ39966931-1AB48DDE-849D-4A45-9BF7-C69E6398CC97Q40444659-C9E008BD-E373-4E08-921B-0653D9B2CE90Q40473692-A5302B2E-CED2-4957-B0A9-611473B72D3BQ42122391-EAC5D8C5-ECEC-4B32-8D9A-028AC57D93C1Q47198424-7506E81D-4961-415D-B3C1-BBEEEBCEC75DQ50277636-1C3FEA7B-F28A-413C-A5C3-403C40AAC2CDQ51097163-AE0BA4B4-658C-46A9-9432-8560F8C7DE75Q51151782-58CECE98-CFB0-4EC0-8E3B-AC5BAA2F45ADQ51654129-ABEB3491-6595-4649-8862-A9D7BE5DB50EQ55146328-6A843499-0804-4D92-B5E2-BE3E9AB73555Q57517715-601D6C83-2A63-4651-9A8A-CDE73EE781D8Q57812469-9D1D7565-3889-4913-BDCD-387ABF8482BCQ58097440-663D6FC0-41F8-4BFD-ABB2-B17ADB204764Q59342609-7C8D08F2-6DEE-4BDF-B9BD-AA6B865ADD5FQ59342611-42736F7B-11F9-4D03-B821-83F5E03E0A08Q59342612-FC028E5A-C561-4629-802E-3843F52F9946Q59342613-762DD337-0C20-4504-AAFD-595E52ED65DFQ59342616-C0336CDD-4BEB-4C4F-B4A5-F67D246D1097Q59342619-FDB20626-5074-498E-8E5F-43AD6D6E0F9BQ59342624-42C209E0-3654-42F5-8EA5-92B074A868D5Q59342627-F11EE254-13F4-43F8-B646-5A0812F0BECBQ60370348-C5EB6D00-83ED-4F6C-803E-6958F8785C2EQ90359608-F4B15A4D-17ED-47D7-AEB1-3BF333C1C9CCQ90672214-24927FAB-D7A7-4003-95D8-6DFA33B84654Q92048294-2068D145-B532-42D8-9007-7956E2877E52
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
N Csaba
@ast
N Csaba
@en
N Csaba
@nl
N Csaba
@sl
Noemi Csaba
@es
type
label
N Csaba
@ast
N Csaba
@en
N Csaba
@nl
N Csaba
@sl
Noemi Csaba
@es
prefLabel
N Csaba
@ast
N Csaba
@en
N Csaba
@nl
N Csaba
@sl
Noemi Csaba
@es
P106
P1153
23972258600
P31
P496
0000-0002-6187-7717